(800) 943-6396

150 Essex St, Millburn, NJ 07041, USA

©2020 by Bon Opus Biosciences, LLC.

CD39 Recombinant Rabbit monoclonal Antibody IgG

SKU: BA112270-100µl

Fig1: Western blot analysis of CD39 on different cell lysate using anti-CD39 antibody at 1/1,000 dilution.

  Positive control:

  Lane 1: Human spleen  

  Lane 2: Mouse placenta 

    Lane 3: Mouse spleen


Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-CD39 antibody. Counter stained with hematoxylin.

Fig3: Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-CD39 antibody. Counter stained with hematoxylin.

Bon Opus Cat. #BA112270
  • Host Species; Species Reactivity

    Rabbit; Human, Mouse, Rat
  • Immunogen

    Recombinant protein
  • Application Summary

    WB, IHC
  • Purification; Formulation

    ProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
  • ALTnames

    Ectonucleoside triphosphate diphosphohydrolase 1, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen
  • Background

    CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes (such as activated B cells) activated NK cells, macrophages, dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke.(ET1704-74)